Clinical Trial Update: Eliquis Regulatory Post Marketing Surveillance

View source ↗

Summary

Regulatory post-marketing safety surveillance update for Eliquis (apixaban) in patients with nonvalvular atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonvalvular Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: NonValvular Atrial Fibrillation | Status: COMPLETED